Monitor upcoming clinical data readouts in H1 and H2 2026 as key catalysts; despite rising operating expenses, extended cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Climb Bio reported Q4 and full-year 2025 financial results, highlighting a cash position of $160.7 million with runway into 2028, while R&D and G&A expenses increased significantly year-over-year. The company continues to advance multiple clinical trials for budoprutug and CLYM116, with key data readouts expected in H1 and H2 2026.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities were $160.7 million as of December 31, 2025, sufficient to fund operations into 2028.
- R&D expenses were $13.7 million in Q4 2025 vs. $6.0 million in Q4 2024; full-year R&D was $46.7 million vs. $14.3 million in 2024.
- G&A expenses were $5.6 million in Q4 2025 vs. $5.0 million in Q4 2024; full-year G&A was $21.2 million vs. $16.0 million in 2024.
- Net loss was $17.5 million in Q4 2025 vs. $8.4 million in Q4 2024; full-year net loss was $59.9 million vs. $73.9 million in 2024.
- EPS was $(0.26) in Q4 2025 vs. $(0.13) in Q4 2024; full-year EPS was $(0.88) vs. $(1.53) in 2024.
- Multiple clinical trials for budoprutug (pMN, ITP, SLE, subcutaneous formulation) and CLYM116 are ongoing, with data expected in H1 and H2 2026.
Financial Impact
Increased R&D spending by $32.4 million YoY, offset by lower acquired IPR&D expense; net loss improved from $73.9M to $59.9M despite higher operating costs.
Risk Factors
- Increasing R&D and G&A expenses may pressure margins if future funding rounds are required before revenue generation.
- Clinical trial delays or negative data could impact valuation given the company's early-stage, pre-revenue status.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249993 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $10.92 | awaiting T+1 | — | $9.59 (−12.23%) |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $9.59 (−8.45%) |
Oct 23, 2026 3d ago | Press Release | $10.34 | awaiting T+1 | — | $9.59 (−7.30%) |
Sep 22, 2026 5w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $9.59 (−32.55%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $9.59 (−34.30%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $9.59 (−41.30%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $9.59 (−31.54%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $9.59 (−27.88%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.59 (+16.58%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.59 (+16.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers